Table III.
Study outcomes stratified by transfusion activity and therapy.
| Periods of active therapy and transfusions* |
||||
|---|---|---|---|---|
| “Watch and wait,” no AT/no trans (n = 3028) |
AT/no trans (n = 487) |
AT/trans (n = 310) |
No AT/trans (n = 886) |
|
| Number of unique patients | 3028 | 337 | 253 | 886 |
| Mean (SD) Charlson comorbidity index score† | 2.00 (2.17) | 2.28 (2.26) | 2.33 (2.23) | 2.86 (2.47) |
| Mean duration, days (SD) | 516 (350) | 153 (130) | 431 (340) | 143 (105) |
| Mean (SD) number of whole/RBC transfusions | 0 | 0 | 0.88 (0.79) | 0.40 (0.52) |
| Number (%) of patients with platelet transfusions | 57 (2) | 20 (4) | 130 (42) | 219 (25) |
| Number (%) of periods with ESA‡ | 0 | 215 (44) | 156 (50) | 0 |
| Number (%) of periods with G-CSF/GM-CSF‡ | 115 (4) | 140 (29) | 128 (41) | 90 (10) |
| Events | n (%) | n (%) | n (%) | n (%) |
| Infection | 1561 (52) | 154 (32) | 149 (48) | 680 (77) |
| Significant bleeding | 775 (26) | 63 (13) | 68 (22) | 432 (49) |
| Inpatient hospitalization | 1120 (37) | 114 (23) | 180 (58) | 739 (83) |
| ER visit | 1398 (46) | 140 (29) | 164 (53) | 676 (76) |
| Incidence per person-year (95% CI) | ||||
| Infection | 0.59 (0.56–0.62) | 0.93 (0.79–1.09) | 1.71 (1.45–2.00) | 1.54 (1.43–1.66) |
| Significant bleeding | 0.22 (0.20–0.24) | 0.34 (0.26–0.43) | 0.63 (0.49–0.79) | 0.64 (0.58–0.70) |
| Inpatient hospitalization | 0.35 (0.33–0.37) | 0.63 (0.52–0.76) | 2.25 (1.94–2.60) | 1.84 (1.71–1.98) |
| ER visit | 0.47 (0.47–0.52) | 0.86 (0.73–1.01) | 2.01 (1.73–2.35) | 1.51 (1.40–1.63) |
SD, standard deviation; RBC, red blood cell; ESA, erythropoietic-stimulating agent; G-CSF/GM-CSF, granulocyte-colony stimulating factor/granulocyte macrophage-colony stimulating factor; ER, emergency room; AT, active therapy; trans, transfusion; CI, confidence interval.
*
Periods of therapy may or may not have included ESAs.
†
Reflects baseline Charlson comorbidity index score and global p < 0.01.
‡
p<0.05.